Pharma supply chain
The Pharma industry is currently facing large uncertainties and complex decisions. Changing the supply chain structure and moving to sell direct to pharmacy (DTP) or restricting the number of wholesalers, is increasingly seen as a viable proposition, particularly in light of the Office of Fair Trading Market Study published in December 2007.
Direct to Pharmacy and PPRS
At Andrew Carr Associates we have first hand experience of successfully leading, managing and adopting DTP for a large pharma manufacturer. We have also been involved in the compliance and development of the Pharmaceutical Price Regulation Scheme (PPRS) for over 10 years. In our opinion, changes to DTP and PPRS should be considered hand in hand.
Considering a move to DTP, or even a restricted wholesaler model, involves many skills including understanding the pharmacy reimbursement mechanism, as well as finance, marketing and change management. The opportunities are different for each manufacturer, but we are confident that our skills can help you with the right decision for your organisation. Even before conducting a feasibility study or considering the wider effects of implementation, we would suggest a desk-top review to look at the numbers as a low cost first step.
